TG Therapeutics
TGTX
354 hedge funds and large institutions have $3.58B invested in TG Therapeutics in 2025 Q3 according to their latest regulatory filings, with 49 funds opening new positions, 104 increasing their positions, 135 reducing their positions, and 47 closing their positions.
4% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 47
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
1% less funds holding
Funds holding: 356 → 354 (-2)
2% less call options, than puts
Call options by funds: $80.5M | Put options by funds: $82M
2% less capital invested
Capital invested by funds: $3.65B → $3.58B (-$71.2M)
1.62% less ownership
Funds ownership: 64.03% → 62.41% (-1.6%)
23% less repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 135
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$52.7M |
| 2 |
ClearBridge Investments
New York
|
+$52.4M |
| 3 |
Man Group
London,
United Kingdom
|
+$28.6M |
| 4 |
Squarepoint
New York
|
+$16.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$38.5M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$29.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$27.7M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$21.4M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.1M |
TGTX Hedge Fund Activity: Q3 2025 in Review
354 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2025, worth a combined $3.58B — down 2% from $3.65B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new TGTX positions and 47 closed out — a net gain of 2 holders — while 104 added to existing stakes and 135 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $52.7M. The largest seller was Wellington Management Group, cutting an estimated $38.5M.
- 354 institutional investors held TG Therapeutics (TGTX) as of Q3 2025, down from 356 in Q2 2025.
- Funds reported $3.58B of TG Therapeutics stock for Q3 2025, down 2% quarter-over-quarter.
- 49 funds opened new TG Therapeutics positions in Q3 2025 and 47 closed out, a net change of +2 holders.
- The largest TG Therapeutics buyer in Q3 2025 was Soleus Capital Management, an estimated $52.7M added.
- The largest TG Therapeutics seller in Q3 2025 was Wellington Management Group, an estimated $38.5M sold.
Based on aggregated 13F filings for Q3 2025.